A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern(1,2). Development of host-directed therapeutics and prophylactics could limit such resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapira, Tirosh, Monreal, I. Abrrey, Dion, Sébastien P., Buchholz, David W., Imbiakha, Brian, Olmstead, Andrea D., Jager, Mason, Désilets, Antoine, Gao, Guang, Martins, Mathias, Vandal, Thierry, Thompson, Connor A. H., Chin, Aaleigha, Rees, William D., Steiner, Theodore, Nabi, Ivan Robert, Marsault, Eric, Sahler, Julie, Diel, Diego G., Van de Walle, Gerlinde R., August, Avery, Whittaker, Gary R., Boudreault, Pierre-Luc, Leduc, Richard, Aguilar, Hector C., Jean, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095466/
https://www.ncbi.nlm.nih.gov/pubmed/35344983
http://dx.doi.org/10.1038/s41586-022-04661-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095466/
https://www.ncbi.nlm.nih.gov/pubmed/35344983
http://dx.doi.org/10.1038/s41586-022-04661-w

Ejemplares similares